RU ₄86 use in developing countries (particularly Bangladesh) was recently discussed at The International Symposium on Antiprogestins, held in Dhaka, Bangladesh, October 7–8, 1991.Google Scholar

Glasier, Anna et al., “Postcoital Contraception with Mifepristone”, The Lancet 337(June 8, 1991):1414–1415.Google Scholar

SCRIP No. 1679/80 December 20/25 1991, p. 24.Google Scholar

Memorandum on Safety and Efficacy of French Abortifacient RU ₄86: Experience in International Markets Support Manufacturer's Claims of Effectiveness and Safety; Questions Remain Regarding Legal, Regulatory and Political Barriers to Drug's Use in the United States, November 27, 1991, 102nd Congress United States House of Representatives Committee on Small Business, Subcommittee on Regulation, Business Opportunities and Energy.Google Scholar

World Health Organization, “Pregnancy Termination with Mifepristone and Gemeprost: A Multicenter Comparison Between Repeated Doses and Single Dose of Mifepristone”, Fertility and Sterility 56(1)(July 1991):32–40.Google Scholar

Altman, Lawrence K., “A Simpler Way to Employ RU₄86 is Reported”, The New York Times, April 9, 1991.Google Scholar

Roussel-Uclaf also includes anemia and malnutrition as contraindications to the use of RU ₄86/prostaglandin, but research is demonstrating that these conditions may be overly cautious as absolute contraindications.Google Scholar

Goldsmith, Marsha F., “As Data on Antiprogesterone Compounds Grow, Societal and Scientific Aspects Are Scrutinized”, Journal of the American Medical Association 265(13)(April 3, 1991):1628–1629.CrossRefGoogle Scholar

Aubény, E., “RU₄86 Combined with PG Analogs in Voluntary Termination of Pregnancy”, Advances in Contraception 7(1991): 339–343.CrossRefGoogle Scholar

Editorial, “A Death Associated with Mifepristone/Sulprostone”, The Lancet 337(April 20, 1991):969–970.Google Scholar

Kalra, P.A. et al., “Cardiac Standstill Induced by Prostaglandin Pessaries”, The Lancet (June 24, 1989): 1460–1461.Google Scholar

Id.Google Scholar

Heard, Michael and Guillebaud, John, “Medical Abortion: Safe, Effective and Legal in Britain”, British Medical Journal 304 (January 25, 1992):195–196.Google Scholar

Id.Google Scholar

Collins, P.W. et al., “Chemistry and Synthetic Development of Misoprostol”, Digestive Diseases and Sciences, 30(11) (November 1985 Supplement):114S–117S.CrossRefGoogle Scholar

Product Information, Cytotec, Physicians Desk Reference, Medical Economics Data, Oradell, NJ 1991: 2060–2062, at 2061.Google Scholar

Norman, J.E. et al., “Uterine Contractility and Induction of Abortion in Early Pregnancy by Misoprostol and Mifepristone”, The Lancet 338 (Nov. 16, 1991):1233–1236.CrossRefGoogle Scholar

Id. p. 1235.Google Scholar

Élisabeth, Aubény and Étienne-émile, Baulieu, “Activite contragestive de l'association au RU ₄86 d'une prostaglandine active par voie orale”, C.R. Acad. Sci. 312 (11) (Series III, 1991):539–545.Google Scholar

Personal Communication, Dr. Étienne-Émile Baulieu, February 3, 1992.Google Scholar

Product information, Cytotec, supra, note 16, p. 2060.Google Scholar

Kapp, Marshall B., “Prescribing Approved Drugs for Non-approved Uses: Physicians' Disclosure Obligations to Their Patients”, 9 Law, Med. and Health Care 21, 22 (1981). In 1972 the F.D.A. proposed a rule that would give it authority to restrict physicians to prescribe drugs only for the specific purposes for which they were approved, but intense physician lobbying kept the rule from becoming final. Although not subject to F.D.A. authority, physicians prescribing drugs for nonapproved uses are governed by medical malpractice law. Id. p. 21.Google Scholar

Schönhöfer, Peter S., “Brazil: Misuse of Misoprostol as an Abortifacient May Induce Malformations”, The Lancet 337(June 22, 1991):1534–1535.CrossRefGoogle Scholar

Id.Google Scholar

Id.Google Scholar

Fonseca, Walter et al., “Misoprostol and Congenital Malformations”, The Lancet 338 (July 6, 1991): 56. Other articles have addressed skull malformations and other anomalies following prostaglandin therapy in pregnant women and in newborns. See, for example: Collins, Francis S. and Mahoney, Maurice J., “Hydrocephalus and Abnormal Digits after Failed First-Trimester Prostaglandin Abortion Attempt,” (involving 15-methyl F2a) J Pediatr 1983 102:620–623; Ringel, Richard et al., “Periosteal Changes Secondary to Prostaglandin Administration,” (involving long-term PGE1 therapy in neonates) J Pediatr 1983 103:251–253 and Hedwig, Hoevels-Guerich et al., “Widening of Cranial Sutures after Long-term Prostaglandin E2 Therapy in Two Newborn Infants,” (involving intravenous administration of PGE2 to newborns for 95 and 97 days) J Pediatr 1984 105:72–74.CrossRefGoogle Scholar

Norman, J.E. et al., supra, note 17, p. 1235.Google Scholar

Product information, Cytotec, supra, note 16, p. 2060.Google Scholar

Swahn, M.L. et al., “Effect of Oral Prostaglandin E2 on Uterine Contractility and Outcome of Treatment in Women Receiving RU ₄86 (Mifepristone) for Termination of Early Pregnancy”, Human Reproduction 4(1)(1989):21–28.Google Scholar

Swahn, M.L. et al., “Oral Administration of RU ₄86 and 9-Methylene PGE2 for Termination of Early Pregnancy”, Contraception 41(5)(1990):461–473.Google Scholar

Frydman, R. et al., “Transplacental Passage of Mifepristone”, The Lancet 2(1985):1252.Google Scholar

Lim, B.H. et al., “Normal Development after Exposure to Mifepristone in Early Pregnancy”, The Lancet 336(July 28, 1990):257–258; Pons, Jean-Claude et al., “Development after Exposure to Mifepristone in Early Pregnancy”, The Lancet 338 (Sept. 21, 1991):763 and Ulmann, André et al., “Development After in utero Exposure to Mifepristone”, The Lancet 338 (Nov. 16, 1991):1270.Google Scholar

Henrion, R., “RU ₄86 Abortions”, Nature 338(1989):110 and Pons, J-C et al., “Development after Exposure to Mifepristone in Early Pregnancy”, The Lancet 338(September 21, 1991):763.Google ScholarPubMed

Grimes, David A. and Cates, Willard Jr., “Complications from Legally-Induced Abortion: A Review”, Obstet and Gynecol Survey 34(3)(1979): 177–191, at 178.CrossRefGoogle Scholar

Sharp curettage has a major complication rate 2.3 times higher than suction curettage. Id. p. 177.Google Scholar

Personal Communication, Dr. Hershel Lawson, Center for Disease Control, Atlanta, GA, February 24, 1992.Google Scholar

Grimes, David A. and Cates, Willard Jr., supra, note 34, p. 186.Google Scholar

Personal Communication, Dr. Herbert Lawson, supra, note 36.Google Scholar

Grimes, David A. and Cates, Willard Jr., supra, note 34, p. 180.Google Scholar

Birman, Chantal, “The Experiences of Women Having an Abortion with RU ₄86”, Women's Global Network for Reproductive Rights Newsletter 31(Oct./Dec., 1989):7–9.Google Scholar

Urquhart, D.R. and Templeton, A.A., “Psychiatric Morbidity and Acceptability Following Medical and Surgical Methods of Induced Abortion”, British Journal of Obstetrics and Gynaecology 98(April 1991):396–399.Google Scholar

Tang, G.W., “A Pilot Study of Acceptability of RU ₄86 and ONO 802 in a Chinese Population”, Contraception 44(5)(November 1991):523–532.Google Scholar

Id. 530.Google Scholar

Id. pp. 526, 530.Google Scholar

Id. p. 529.Google Scholar

See Winikoff, Beverly et al., “Studying the Acceptability and Feasibility of Medical Abortion,”Law, Medicine & Health Care 20:2 (this issue).Google Scholar

Coyaji, Banoo, “Safe Motherhood and RU-₄86 in the Third World”, People 17(3)(1990):13–15.Google Scholar

Royston, Erica, Armstrong, Sue, eds., Preventing Maternal Deaths, (Geneva: World Health Organization 1989): Pp. 31, 35.Google Scholar

Id. p. 111.Google Scholar

The anti-choice movement opposing RU ₄86 is not limited to industrialized countries. The Pro-Life Society of Zambia has vowed to fight RU ₄86 should it come into use there. Andindilile, Michael, “Pro-Life Society to Fight Abortion Drug”, Times of Zambia, Saturday, July 11, 1990.Google Scholar

See Renata, Klein et al., RU ₄86: Misconceptions, Myths and Morals, (Australia: Spinifex Press Pty Ltd. 1991) and Kabir, Sandra and Germain, Adrienne, “Is RU ₄86 Likely to be Appropriate for Women in Bangladesh?” (Paper prepared for the International Symposium on Antiprogestins, unpublished, 1991).Google Scholar

Riding, Alan, “Abortion Politics Are Said to Hinder Use of French Pill”, The New York Times, July 29, 1990: Pp. 1, 9.Google Scholar

The French National Advisory Committee on Ethics on the Life Sciences and Health concluded that RU ₄86/prostaglandin falls within the scope of legislation on abortion. Knoppers, Bartha M. et al., “Abortion Law in Francophone Countries,” 38 Am J of Comparative Law 889, 901 (1990). The 1967 Abortion Act in the U.K. was amended in 1990 to permit the provision of nonsurgical abortions. Human Fertilisation and Embryology Act 1990, Sect. 37 (3). For a discussion of the legal developments regarding RU ₄86 in France and the United Kingdom, see Reed Boland, “RU ₄86 in France and England,” in this issue of Law, Medicine & Health Care.Google Scholar

See Glasier, Anna et al., supra, note 2.Google Scholar

Henshaw, Stanley K., “Induced Abortion: A World Review, 1990”, Family Planning Perspectives 22(2)(1990): 76–89.CrossRefGoogle Scholar

Id.Google Scholar

In the past two decades, 65 jurisdictions have liberalized their abortion laws while four countries have limited the grounds for the procedure. Cook, Rebecca J., “Abortion Laws and Policies: Challenges and Opportunities”, Int. J. Gynecol. Obstet. Suppl. 3 (1989): 61–87, at 61.CrossRefGoogle Scholar

In the United States, the states of Utah and Louisiana and the territory of Guam have passed legislation making abortion a crime (with exceptions). Utah S.B. No. 23 (1991); LAS-R.S. 14:87 (1992) [held unconstitutional in Sojourner, T. et al. v. Roemer and Okpalobi v State, 772 F. Supp. 930 (E. D. La.), (Aug. 7, 1991)]; Guam Bill No. 848 [held unconstitutional in Guam Society of Obstetricians and Gynecologists v. Joseph F. Ada, 972 F. 2nd 1366 (April 14, 1992)].Google Scholar

Yen, S.S.C., “The Human Menstrual Cycle,” in Yen, S.S.C. and Jaffe, R., eds., Reproductive Endocrinology, Physiology, Pathophysiology and Clinical Management, (Philadelphia: W.B. Saunders, 1986), second ed., p. 200.Google Scholar

See Cook, Rebecca J., “Anti-Progesterones and the Law”, IPPF Medical Bulletin 20(5)(1986):2–3. Cook advocates that laws should accommodate the use of antiprogesterones as a last chance contraceptive for women with amenorrhea of up to 35 days from the first day of the last menstrual period. The law would reflect the biological reality that not all women have regular, 28-day menstrual cycles. Id. p. 3.Google Scholar

1978 (3 April) Penal Law, Sec. 16.3.Google Scholar

Cook, Rebecca J., supra, note 57.Google Scholar

In section 31.20, Guam's abortion law defines abortion as “the purposeful termination of a human pregnancy after implantation of a fertilized ovum….” Guam Bill No. 848 (1989)(emphasis added); the Utah law defines abortion as “the termination or attempted termination of human pregnancy after implantation of a fertilized ovum…” Utah S.B. No. 23, Section 76-7-301 (1) (1991).Google Scholar

Republic of Zambia, Termination of Pregnancy Act, Chapter 554 of the Laws of Zambia (1972).Google Scholar

Section 3209 of the Pennsylvania Abortion Control Act requires that, before a physician may perform an abortion on a married woman, the woman must sign a statement that she has notified her husband of her intended abortion (each form must bear a notice that false statements are punishable by law). 18 Pa. Cons. Stat. Ann. §§ 3201–3220 (1983 & Supp. 1991). This section was declared unconstitutional by the United States Court of Appeals, Third Circuit, in Planned Parenthood of Southeastern Pennsylvania v. Casey, 947 F2d. 682 (1991).Google Scholar

Knoppers, Bartha M. et al., supra, note 53, p. 914, citing France: Code de la santé publique, art. 162–5, as amended by Loi de 1975; Belgium: Code pénal, art. 350(3); Luxembourg: Code pénal, art 353.Google Scholar

On average the mortality rate for abortion increases by 30 percent with each passing week of gestation. The mortality rate at nine to ten weeks of gestation is one-fourth the mortality rate at 13 to 15 weeks of gestation. Castadot, Robert G., “Pregnancy termination: techniques, risks, and complications and their management,” Fertility and Sterility 45(1) (1986):5–17, at 8.Google ScholarPubMed

Cook, Rebecca J., supra, note 57.Google Scholar

Paxman, J.M. and Barberis, M., “Menstrual Regulation and the Law”, Int. J. Gynecol. Obstet. 17(1980):493–503, at 16, 17.CrossRefGoogle Scholar

Id.Google Scholar

From four to ten weeks of gestation, these signs are considered “probable manifestations” of pregnancy:Google ScholarGoogle Scholar

Gestational trophoblastic tumors arise in fetal rather than maternal tissue. April G. O'Quinn and Barnard, David E., “Gestational Trophoblastic Diseases” in Current Obstetric & Gynecologic Diagnosis & Treatment, Pernoll, Martin L. and Benson, Ralph C., eds., Sixth Edition, (Norwalk, Connecticut: Appleton & Lange, 1987): 891–900, at 891.Google Scholar

Only pregnancy tests that are radioimmunoassay for the ß- subunit of the hCG are sensitive and specific for early pregnancy. In immunologic pregnancy tests, cross-reaction can occur with luteinizing hormone (LH). Thus, any condition that stimulates release of LH from the anterior pituitary may cause a false-positive reaction on the test. Antipsychotic agents and tranquilizers may cause release of LH. Test results are also altered by proteinuria and immunologic disease. Taylor, Cathy M. and Pernoll, Martin L., supra, note 71, pp. 166–167.Google Scholar

Irani, Kathy R. et al., “Menstrual Induction: Its Place in Clinical Practice”, Obstetrics and Gynecology 46(5) (November 1975):596–598, at 598.Google Scholar

World Health Organization, “Menstrual Regulation by Intramuscular Injections of 16-Phenoxy-Tetranor PGE2 Methyl Sulfonylamide or Vacuum Aspiration. A Randomized Multicentre Study”, British Journal of Obstetrics and Gynaecology, 94 (October 1987): 949–956.CrossRefGoogle Scholar

Penal Code Act XLV, Chapter XVI—Of Offences affecting the Human Body (1860).Google Scholar

Government of the People's Republic of Bangladesh, Population Control and Family Planning Division, Memorandum: Guidelines for Menstrual Regulation (MR), Memo No. 5-14/MCH- FP/Trg./80/358/1(96). Dated 25 January 1980. The memorandum cites an Extract from Report on Legal Aspects of Population Planning in Bangladesh, Chapter II – Abortion, p. 31: “…many Family Planning Clinics are carrying out the post-contraceptive method of 'Menstrual Regulation' as a means of birth control which does not come under Section 312 of the Penal Code. Under [the] statutory scheme, pregnancy is an essential element of the crime of abortion, but the use of menstrual regulation makes it virtually impossible for the prosecutor to meet the required proof…” Id.Google Scholar

In France, the 1939 amendment to the 1810 Napoleonic Penal Code made it a crime to perform abortion on a pregnant woman “or a woman who is presumed to be pregnant.” Knoppers, Bartha M. et al., supra, note 53, p. 894; Under Section 58 of the Offences Against the Person Act (1861) and Section 1 of the 1929 Infant Life (Preservation) Act, abortion was defined as “unlawfully using any instrument or other means with the intent to procure a miscarriage of any woman.” Paxman, J. and Barberis, M., supra, note 69, p. 496.Google Scholar

Id.Google Scholar

Henshaw, Stanley K., “Induced abortion: A world review: 1990”, Family Planning Perspectives 22(2)(March/April 1990):76–89.CrossRefGoogle Scholar

Lewin, Tamar, “Hurdles Increase for Many Women Seeking Abortions,” The New York Times, Sunday, March 15, 1992: 1 and 11, at 11. From 1977–1988, 110 cases of arson, firebombing or bombing were reported against pro-choice facilities and organizations in the United States. Grimes, David A. et al., “An Epidemic of Antiabortion Violence in the United States”, Am J Obstet Gynecol 165 (1991):1263–1268, at 1264.Google Scholar

Center for Disease Control, “Abortion Surveillance: Preliminary Analysis—United States, 1989”, MMWR 40(47)(November 29, 1991):817–818.Google Scholar

Chen, A.J. et al., “Legalized Abortion: The Singapore experience”, Studies in Family Planning 16(3)(May/June 1985):170–178.CrossRefGoogle Scholar

Id.Google Scholar

Baird, David T., et al., “Prostaglandin and Antigestigens for the Interruption of Early Pregnancy”, Journal of Reproductive Fertility, Suppl. 36(1988):173–179.Google Scholar

Rodger, Mary W. and Baird, David T., “Blood Loss Following Induction of Early Abortion Using Mifepristone (RU ₄86) and a Prostaglandin Analogue (Gemeprost)”, Contraception 40(4)(October 1989):439–447.CrossRefGoogle Scholar

Moore, Pamela J., “Maternal Physiology During Pregnancy,” in Current Obstetric & Gynecologic Diagnosis & Treatment, Pernoll, Martin L. and Benson, Ralph C., eds., Sixth Edition, (Norwalk, Connecticut: Appleton & Lange, 1987): 129.Google Scholar

Id.Google Scholar

Rodger, Mary W. and Baird, David T., supra, note 86.Google Scholar

Coyagi, Banoo, supra, note 47, p. 15.Google Scholar

Kabir, Sandra and Germain, Adrienne, supra, note 51, p. 8.Google Scholar

World Health Organization, “A Cross-Cultural Study of Menstruation: Implications for Contraceptive Development and Use”, Studies in Family Planning 1981 12(1):3–16.CrossRefGoogle Scholar

SCRIP No. 1382, February 1, 1989, p. 23.Google Scholar

“Decline in NHSC Physicians Threatens Patient Care”, AJPH 1990 80(11):1395.CrossRefGoogle Scholar

Lewin, Tamar, supra, note 81, p. 11.Google Scholar

Henshaw, Stanley K., “The Accessibility of Abortion Services in the United States”, Family Planning Perspectives 1991 23(6):246–252.CrossRefGoogle Scholar

Id. p. 248.Google Scholar

Lewin, Tamar, supra, note 81, p. 11.Google Scholar

In 1988, regulations promulgated by the U.S. Department of Health and Human Services directed that family planning clinics, as a condition of receiving federal subsidies under Title X of the Family Planning Services and Population Act, may not discuss abortion with a client, even if a client initiates the discussion. 42 CFR §59.1-§59.10 (1989). The regulations have not been enforced because of legal challenges and because of the failure of the Health and Human Services Department to issue detailed enforcement guidelines. In 1989 the U.S. Supreme Court upheld the Title X regulations in Rust v. Sullivan, 111 S. Ct. 1759 (1991); Jeremy Sugarman and Madison Powers, “How the Doctor Got Gagged,” Journal of the American Medical Association 266 (23) (December 18, 1991):3323–3327. On March 20, 1992, a guidance memorandum was issued to the ten Department of Health and Human Services regional health administrators to clarify implementation of the regulations. The guidance memorandum has caused considerable confusion on how Title X regulations are to be implemented. Philip J. Hilts, “White House Allows Some Advice At Public Clinics About Abortion,” The New York Times, Saturday, March 21, 1992, pp. 1 and 5; Washington Memo, “Bush Administration Issues Plan for Implementation of Abortion 'Gag Rule,'” April 1, 1992, pp. 1–4.Google Scholar

For an excellent review of this issue, see Sereen Thaddeus and Deborah Maine, Too Far to Walk: Maternal Mortality in Context, Prevention of Maternal Mortality Program, Center of Population and Family Health, Columbia University, 1990.Google Scholar

Cook, Rebecca J. and Maine, Deborah, “Spousal Veto over Family Planning Services, Am. J. Pub. Health (1987) 77:339–340.CrossRefGoogle ScholarPubMed

These are actual statistics presented in an evaluation of menstrual regulation services in rural clinics in Bangladesh. See Kay, Bonnie J. and Kabir, Sandra M., “A Study of Costs and Behavioral Outcomes of Menstrual Regulation Services in Bangladesh”, Soc. Sci. Med. 26(6)(1988): 597–604.CrossRefGoogle Scholar

Maine, Deborah, Safe Motherhood Programs: Options and Issues, Center for Population and Family Health, School of Public Health, Faculty of Medicine, Columbia University, New York, 1991, p. 42.Google Scholar

Id.Google Scholar

McLaurin, Katie et al., “Health Systems' Role in Abortion Care: The Need for a Pro-Active Approach”, Issues in Abortion Care 1, (Carrboro, North Carolina: IPAS, 1991).Google Scholar

Drug Facts and Comparisons, The Facts and Comparisons Divisions, (St. Louis:J.B. Lippincott Company, 1988):328C.Google Scholar

For a discussion of the relative risks of introducing RU ₄86/prostaglandin into developing countries, see Woodroffe, Caroline, “Medical abortion and the availability of ₄86—are women's rights being ignored in developing countries?” Health Policy and Planning 7(1) (1992):77–81.Google Scholar

Kolata, Gina, “Patients Turning to Illegal Pharmacies”, The New York Times, Monday, November 4, 1991, pp. A-1 and A-10.Google Scholar

Lee, P. et al., “Drug Promotion and Labeling in Developing Countries: An Update”, J Clin Epidemiol 44(suppl II)(1991):49S–55S.Google Scholar

Wolffers, Ivan, et al., Marketing Fertility: Women, Menstruation and the Pharmaceutical Industry (Amsterdam: WEMOS, May 1989); Coelho, H., “Selling Abortifacients Over the Counter in Pharmacies in Fortaleza, Brazil,” The Lancet 338(July 27, 1991):147; de Oddone, Nelly Krayacich et al., “Paraguayan Pharmacies and the Sale of Pseudo-Abortifacients”, J. Biosoc. Sci. 1991 2.3:201–209.Google Scholar

See Charo, Alta, “A Political History of RU-₄86,” In Hanna, K.E., ed., Bio-Medical Politics (Washington, D.C.: National Academy Press, 1991):43–91.Google Scholar

“RU ₄86 Goes into Widespread Use in UK”, IPPF Open File, January 1992, p.9.Google Scholar

Id.Google Scholar

102nd Congress, United States House of Representatives, supra, note 4, p. 19.Google Scholar

“Drugs for the Treatment of Peptic Ulcers”, The Medical Letter, vol. 33 (issue 858), November 29, 1991. The wholesale price for 800 μgs. per day for 30 days is listed as $71.59. This gives a wholesale price of $1.19 for 400 μgs.Google Scholar

Woodroffe, Caroline, supra, note 107, p. 80.Google Scholar